Brought to you by 
ShangPharma goes private in management buy-out
28 Feb 2013
Executive Summary
Chinese CRO ShangPharma Corp., which debuted on the NYSE less than two years ago, received a non-binding proposal from Chairman and CEO Michael Xin Hui and affiliates (who together own 54%) and TPG Capital (which has an 11% stake) to acquire all of the company’s outstanding shares for a price between $8.50-9.50 per ADS.
Deal Industry
- Contract Research Organization-CRO
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Buy-out
- Includes Contract
- Partial Acquisition
- Payment Includes Cash for Equity
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
ShangPharma goes private in management buy-out
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice